Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Jul;60(5):376-81.
doi: 10.1007/BF00295758.

Teratologic studies on the Himalayan rabbit: new aspects of thalidomide-induced teratogenesis

Affiliations

Teratologic studies on the Himalayan rabbit: new aspects of thalidomide-induced teratogenesis

H Sterz et al. Arch Toxicol. 1987 Jul.

Abstract

The aim of our study was to determine the period of maximum sensitivity for the induction of characteristic malformations with thalidomide (TH) in Himalayan rabbits. TH was administered orally in different doses (50, 100, 150 and 200 mg/kg) four times at 24-h intervals starting at 192 h of gestation. The malformations affected various organs: renal defects (dysplasia) and limb anomalies (dysmelia)--which had never occurred spontaneously in this strain--appeared as dose-dependent effects of the drug. By administering single doses of TH (200 and 300 mg/kg body wt) between hours 192 and 264 of gestation, we discovered the different periods of maximum sensitivity for induction of renal dysplasia (clearly prior to the 220th h of gestation) and dysmelia (between hours 230 and 240 of gestation). The types of limb malformations that we observed in the rabbit were identical to those produced in man following the intake of TH. Three doses of TH (300 mg/kg each) given between hours 222 and 228 of gestation produced characteristic limb malformations in 9 of 11 litters treated. These results make it possible to conduct in vivo experiments on a readily available laboratory animal with minor drug exposure of the gravid dam and under avoidance of toxic side effects.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arzneimittelforschung. 1979;29(8):1146-50 - PubMed
    1. Biochem Pharmacol. 1984 May 1;33(9):1471-7 - PubMed
    1. Teratology. 1980 Oct;22(2):179-82 - PubMed
    1. Arzneimittelforschung. 1969 Feb;19(2):167-9 - PubMed
    1. Teratology. 1971 Feb;4(1):75-85 - PubMed

LinkOut - more resources